Project Grant R01AI198054
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $993K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute $809,479 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered native HIV envelope glycoprotein trimers that induce broadly neutralizing antibodies (BNAbs) targeting the CD4-binding site. The research addresses two critical limitations in current HIV-1 vaccine strategies. First, existing boosting immunogens lack the stringency...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $276,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate HIV-1 envelope-C3D constructs on nanoparticles for structure, function, and immunogenicity. Scripps will assess ENV-C3D fusion candidates carrying two and three copies of C3D domains per GP160 subunit (with or without Fc domain) in C57BL/6 and alloy mice. The research will measure germinal...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the Scripps Research Institute $937,343 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research optimizing vaccine-elicited cross-neutralizing antibody responses targeting the HIV envelope (Env) trimer apex to inform broadly neutralizing antibody (BnAb) development for...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $511,531 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance HIV vaccine development using a lipid nanodisc platform. The project, designated R01AI192143, addresses challenges in engineering transmembrane HIV envelope glycoprotein (ENV) vaccine candidates by incorporating them into stable lipid nanodiscs using membrane scaffold proteins and...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $806,623 on May 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R56AI194947) to elucidate the structural and kinetic basis of HIV-1 broadly neutralizing antibody responses, focusing on transient states and intermediates in antibody-antigen interactions that govern affinity maturation and neutralization breadth. The funded research will employ structural and kinetic...
- The National Institute of Allergy and Infectious Diseases awarded The Salk Institute for Biological Studies $161,868 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the mutational pathways and molecular mechanisms through which drug resistance evolves against latest-generation antiretroviral therapy drugs for HIV. The research combines three complementary approaches. First, the work uses Potts sequence-covariation fitness landscape models...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $251,875 on May 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to explore the structural basis of antibody-mediated Fc-effector functions in HIV-1 immune complexes. The research establishes a cryo-electron microscopy platform to directly observe how antibodies bound to HIV-1 envelope glycoproteins on virions are recognized by Fc gamma receptors on plasma membrane blebs and...
- The National Institute of Allergy and Infectious Diseases (NIAID), within the Department of Health and Human Services National Institutes of Health, awarded $515,625 to The Salk Institute for Biological Studies on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing Project Grant R21AI197945). The award funds research into molecular pathways leading to drug resistance in HIV-1 integrase. The project investigates how and why distinct...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $874,531 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model dynamic CD8+ T cell–virus interactions in post-treatment control of HIV. The project comprehensively defines mechanistic features of CD8+ T cell responses that most strongly relate to control of HIV after stopping antiretroviral therapy. Research will examine...
- The National Institute of Allergy and Infectious Diseases awarded Applied Biomedical Science Institute $976,318 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the molecular mechanisms underlying ultralong complementarity-determining region H3 (CDR H3) antibodies produced by cattle. The project investigates two major objectives. The first examines the atypical V(D)J recombination event that generates ultralong CDR H3 genes, specifically the...